Jinwon Life Sciences Submits Application for Phase 2 Clinical Trial Approval of COVID-19 Treatment to US FDA

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 28th that it has submitted a Phase 2 clinical trial approval application for GLS-1027, a treatment that suppresses severe lung disease caused by cytokine storm after infection with the novel coronavirus disease (COVID-19), to the U.S. FDA.

The company explained, "GLS-1027 is an oral low-molecular-weight drug whose safety has already been confirmed through clinical studies on healthy adults, and animal studies have demonstrated its excellent efficacy in inflammatory and autoimmune diseases."

It added, "In particular, since GLS-1027 has shown the ability to suppress multiple pro-inflammatory substances (cytokines) generated after COVID-19 infection, this clinical study aims to verify whether GLS-1027 can prevent and treat severe pneumonia that induces serious illness and death following COVID-19 virus infection."